Overview

Evaluate the Efficacy and Safety of HLX10 in Chronic Hepatitis B Patients

Status:
Recruiting
Trial end date:
2022-07-30
Target enrollment:
Participant gender:
Summary
A multiple-center, open-label, Phase II clinical trial to evaluate the safety and the efficacy of HLX10 in chronic hepatitis B patients.
Phase:
Phase 2
Details
Lead Sponsor:
Henlix, Inc
Treatments:
Antibodies
Antibodies, Monoclonal
Antineoplastic Agents, Immunological
Entecavir
Immunoglobulins
Tenofovir